AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An isolated human monoclonal antibody that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.

2. **(Previously presented)** The antibody of Claim 1, further comprising a light chain polypeptide having the sequence of SEQ ID NO.:64.

3.-40. **(Cancelled)**

3 ~~41.~~ **(Currently amended)** An isolated antibody immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 1.

4 ~~42.~~ **(Withdrawn previously presented)** A method for assaying the level of monocyte chemo-attractant protein (MCP-1) in a patient sample, comprising:

contacting the anti-MCP-1 antibody of Claim 1 with the patient sample; and

detecting the level of MCP-1 in the patient sample.

5 ~~43.~~ **(Withdrawn)** A method according to Claim ~~42~~ 4, wherein the patient sample is blood.

6 ~~44.~~ **(Currently amended)** A composition, comprising the antibody ~~or fragment thereof~~ of Claim 1, and a pharmaceutically acceptable carrier.

7 ~~45.~~ **(Withdrawn amended)** A method of effectively treating a neoplastic disease, comprising:

selecting an animal in need of treatment for a neoplastic disease; and

administering to said animal a therapeutically effective dose of the antibody of Claim 1.

8 ~~46.~~ **(Withdrawn amended)** The method of Claim ~~45~~ 7, wherein said neoplastic disease is selected form the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and ~~prostrate~~ prostate cancer.

47. **(Withdrawn amended)** A method of effectively treating inflammatory conditions, comprising:

selecting an animal in need of treatment for an inflammatory condition; and

administering to said animal a therapeutically effective dose of the antibody of Claim 1.

48. **(Withdrawn)** The method of Claim 47, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, and multiple sclerosis.

49. **(Cancelled)**

50. **(Cancelled)**

9 ~~51.~~ **(Currently amended)** An isolated human monoclonal antibody that binds to the sequence ISVQRLASYRRITSSK (SEQ ID NO.: 150).

52. **(Cancelled)**

10 ~~53.~~ **(Previously presented)** A method of manufacturing the antibody of Claim 1, comprising:

immunizing a mammal with a synthetic peptide of MCP-1;

recovering a lymphatic cell that expresses the antibody of Claim 1 from the immunized mammal; and

fusing the lymphatic cell with a myeloid-type cell to prepare a hybridoma cell that produces the antibody of Claim 1.

11 ~~54.~~ **(New)** The antibody of Claim 1, wherein said antibody is conjugated to a therapeutic agent.

12 ~~55.~~ **(New)** The antibody of Claim 11 ~~54~~, wherein said therapeutic agent is a toxin.

13 ~~56.~~ **(New)** The antibody of Claim 12 ~~55~~, wherein said toxin is an immunotoxin.

14 ~~57.~~ **(New)** The antibody of Claim 11 ~~54~~, wherein said therapeutic agent is a chemotherapeutic agent.

15 ~~58.~~ **(New)** The antibody of Claim 14 ~~57~~, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

16 ~~59.~~ **(New)** The antibody of Claim 11 ~~54~~, wherein said therapeutic agent is a steroid.

17 ~~60.~~ **(New)** The antibody of Claim 11 ~~54~~, wherein said therapeutic agent is a radioisotope.

18 ~~61.~~ **(New)** The antibody of Claim 17 ~~60~~, wherein said radioisotope is selected from the group consisting of ^{3}H, ^{14}C, ^{15}N, ^{35}S, ^{90}Y, ^{99}Tc, ^{111}In, ^{125}In, and ^{131}I.

19 ~~62.~~ **(New)** The antibody of Claim 9 ~~51~~, wherein said antibody is conjugated to a therapeutic agent.

20 ~~63.~~ **(New)** The antibody of Claim 19 ~~62~~, wherein said therapeutic agent is a toxin.

21 ~~64~~. (New) The antibody of Claim ~~63~~ 20, wherein said toxin is an immunotoxin.

22 ~~65~~. (New) The antibody of Claim ~~63~~ 20, wherein said therapeutic agent is a chemotherapeutic agent.

23 ~~66~~. (New) The antibody of Claim ~~65~~ 22, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

24 ~~67~~. (New) The antibody of Claim ~~65~~ 22, wherein said therapeutic agent is a steroid.

25 ~~68~~. (New) The antibody of Claim ~~65~~ 22, wherein said therapeutic agent is a radioisotope.

26 ~~69~~. (New) The antibody of Claim ~~68~~ 25, wherein said radioisotope is selected from the group consisting of ^{3}H, ^{14}C, ^{15}N, ^{35}S, ^{90}Y, ^{99}Tc, ^{111}In, ^{125}In, and ^{131}I.

27 ~~70~~. (New) The antibody of Claim 1, wherein said antibody neutralizes the activity of MCP-1.

28 ~~71~~. (New) The antibody of Claim ~~41~~ 3, wherein said antibody neutralizes the activity of MCP-1.

29 ~~72~~. (New) The antibody of Claim ~~51~~ 9, wherein said antibody neutralizes the activity of MCP-1.

30 ~~73~~. (New) The antibody of Claim 1, wherein said antibody binds to MCP-1 with a dissociation constant (K_D) of approximately 3.0 pM.

31 ~~74~~. (New) The antibody of Claim ~~73~~ 30, wherein said dissociation constant is 3.3 pM.

32 ~~75~~. (New) The antibody of Claim ~~41~~ 3, wherein said antibody binds to MCP-1 with a dissociation constant (K_D) of approximately 3.0 pM.

33 ~~76~~. (New) The antibody of Claim ~~75~~ 32, wherein said dissociation constant is 3.3 pM.

34 ~~77~~. (New) The antibody of Claim ~~51~~ 9, wherein said antibody binds to MCP-1 with a dissociation constant (K_D) of approximately 3.0 pM.

35 ~~78~~. (New) The antibody of Claim ~~77~~ 34, wherein said dissociation constant is 3.3 pM.

36 ~~79~~. (New) An isolated human monoclonal antibody binding fragment that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.

37 ~~80~~. (New) The antibody binding fragment of Claim ~~79~~ 36, further comprising a light chain polypeptide having the sequence of SEQ ID NO.: 64.

38 ~~81~~. (New) The antibody binding fragment of Claim ~~79~~ 36, wherein said binding fragment is selected from the group consisting of Fab, Fab', $F(ab')_2$, and F_v.

39 ~~82~~. (New) The antibody binding fragment of Claim ~~79~~ 36, wherein said fragment is conjugated to a therapeutic agent.